COVID-19 Still Dampens Neurocrine Revenues Despite Industry’s Q3 Uptick
A Pair Of Clinical Holds Hinders The Pipeline
The pandemic has hit psychiatry offices hard, and the company’s management said it anticipates flat sequential revenues in Q4.
You may also be interested in...
Ongentys, now approved as adjunctive therapy in Parkinson’s disease, will offer a convenience advantage over generic COMT inhibitors. The company will delay launch due to pandemic and manufacturing issues.
The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.